StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
901
This month
5
This week
3
This year
34
Yesterday
1
Publishing Date
2023 - 12 - 11
5
2023 - 10 - 20
4
2023 - 06 - 05
4
2023 - 02 - 21
4
2023 - 01 - 09
4
2022 - 12 - 12
4
2022 - 12 - 07
4
2022 - 10 - 24
5
2022 - 10 - 06
4
2022 - 09 - 06
4
2022 - 08 - 25
4
2022 - 07 - 13
4
2022 - 06 - 24
4
2022 - 06 - 21
5
2022 - 06 - 07
4
2022 - 05 - 31
5
2022 - 05 - 24
7
2022 - 05 - 23
6
2022 - 05 - 11
4
2022 - 05 - 03
4
2022 - 05 - 02
4
2022 - 03 - 29
4
2022 - 03 - 28
4
2022 - 03 - 14
4
2022 - 03 - 07
4
2022 - 03 - 01
6
2022 - 02 - 28
6
2022 - 02 - 01
4
2022 - 01 - 24
6
2021 - 12 - 17
4
2021 - 12 - 14
7
2021 - 12 - 09
4
2021 - 12 - 06
8
2021 - 12 - 01
4
2021 - 11 - 18
6
2021 - 11 - 05
5
2021 - 10 - 26
4
2021 - 10 - 25
4
2021 - 09 - 29
6
2021 - 08 - 16
3
2021 - 08 - 05
4
2021 - 07 - 15
3
2021 - 07 - 06
3
2021 - 06 - 29
4
2021 - 06 - 28
3
2021 - 06 - 17
5
2021 - 06 - 08
4
2021 - 06 - 07
5
2021 - 06 - 03
3
2021 - 05 - 25
3
2021 - 05 - 24
3
2021 - 05 - 06
3
2021 - 05 - 03
5
2021 - 04 - 23
5
2021 - 04 - 13
3
2021 - 03 - 19
3
2021 - 01 - 26
3
2020 - 12 - 29
3
2020 - 12 - 10
3
2020 - 12 - 03
3
Sector
Commercial services
3
Communications
18
Consumer durables
1
Consumer non-durables
3
Electronic technology
1
Finance
1
Health care and social assistance
1
Health services
5
Health technology
814
Manufacturing
27
Mining, quarrying, and oil and gas extraction
1
N/a
9
Producer manufacturing
2
Professional, scientific, and technical services
8
Tags
Alliances
104
Als
190
Alzheimer's
104
Alzheimer’s
151
Antibody
100
Application
135
Approval
167
Biopharma
167
Biotech
133
Biotech-bay
105
Biotech-beach
115
Cancer
788
Cell
121
China
108
Clearance
115
Clinical trials
130
Clinical-trials-phase-i
219
Clinical-trials-phase-ii
1194
Clinical-trials-phase-iii
901
Collaboration
137
Conference
350
Covid
315
Covid-19
237
Deadline
140
Disease
539
Drug
219
Enroll
318
Europe
134
Events
122
Fda
374
Genetown
143
Growth
146
Iot
125
Meeting
231
N/a
4274
Ongoing
249
Pharm-country
156
Pharma
157
Pharmaceuticals
256
Phase 1
750
Phase 1b
124
Phase 2
1215
Phase 2b
438
Phase 3
854
Positive
944
Potential
113
Presentation
218
Publication
115
Report
97
Research
594
Results
1018
Study
294
Therapeutics
874
Therapy
361
Topline
406
Treatment
1036
Trial
6814
Trials
569
Update
148
Vaccine
282
Entities
Abbvie inc.
25
Abeona therapeutics inc.
4
Actinium pharmaceuticals, inc.
5
Aerie pharmaceuticals, inc.
4
Aldeyra therapeutics, inc.
12
Alnylam pharmaceuticals, inc.
14
Amgen inc.
9
Annovis bio, inc.
5
Apellis pharmaceuticals, inc.
5
Arcutis biotherapeutics, inc.
5
Ascendis pharma a/s
4
Astrazeneca plc
16
Bausch health companies inc.
4
Beigene, ltd.
11
Biofrontera inc.
4
Biogen inc.
4
Bristol-myers squibb company
20
Can-fite biopharma ltd
5
Cel-sci corporation
5
Clovis oncology, inc.
5
Concert pharmaceuticals, inc.
4
Deciphera pharmaceuticals, inc.
5
Edesa biotech, inc.
4
Eli lilly and company
32
Exelixis, inc.
15
Geron corporation
7
Gilead sciences, inc.
14
Glaxosmithkline plc
4
Greenwich lifesciences, inc.
7
Horizon therapeutics public limited company
11
Humanigen, inc.
7
Incyte corporation
12
Innoviva, inc.
4
Ionis pharmaceuticals, inc.
8
Johnson & johnson
52
Marinus pharmaceuticals, inc.
5
Mediwound ltd.
4
Merck & company, inc.
40
Moderna, inc.
6
Morphosys ag
4
Nektar therapeutics
5
Novartis ag
4
Novavax, inc.
4
Novocure limited
4
Ocugen, inc.
4
Oramed pharmaceuticals inc.
4
Orange
18
Pfizer, inc.
15
Regeneron pharmaceuticals, inc.
9
Sanofi
80
Scynexis, inc.
5
Seagen inc.
4
Seres therapeutics, inc.
6
Sierra oncology, inc.
5
Takeda pharmaceutical company limited
23
Teva pharmaceutical industries ltd
8
Therapeutic solutions international, inc.
7
Urogen pharma ltd.
5
Veru inc.
6
Vistagen therapeutics, inc.
5
Symbols
ABBV
25
ABEO
4
AERI
4
ALDX
12
ALNY
14
AMGN
9
ANVS
5
APLS
5
ARQT
5
ASND
4
ATNM
5
AZN
16
BFRI
4
BGNE
11
BHC
4
BIIB
4
BMY
20
CANF
5
CLVS
5
CNCE
4
CVM
5
DCPH
5
EDSA
4
EXEL
15
FNCTF
18
GERN
7
GILD
14
GLSI
7
GSK
4
HGEN
7
HZNP
11
INCY
12
INVA
4
IONS
8
JNJ
52
LLY
32
MCRB
6
MDWD
4
MOR
4
MRK
40
MRNA
6
MRNS
5
NKTR
5
NVAX
4
NVCR
4
NVS
4
OCGN
4
ORMP
4
PFE
15
REGN
9
SCYX
5
SNY
80
SNYNF
67
SRRA
5
TAK
23
TEVJF
8
TSOI
7
URGN
5
VERU
6
VTGN
5
Exchanges
Amex
27
Nasdaq
707
Nyse
227
Crawled Date
2023 - 12 - 11
4
2023 - 10 - 20
4
2023 - 06 - 05
4
2023 - 01 - 09
4
2022 - 12 - 12
4
2022 - 12 - 07
4
2022 - 10 - 24
5
2022 - 10 - 06
4
2022 - 09 - 06
4
2022 - 08 - 25
4
2022 - 07 - 13
4
2022 - 06 - 24
4
2022 - 06 - 21
5
2022 - 06 - 07
4
2022 - 05 - 31
5
2022 - 05 - 27
4
2022 - 05 - 25
4
2022 - 05 - 24
6
2022 - 05 - 23
6
2022 - 05 - 11
4
2022 - 05 - 03
4
2022 - 05 - 02
4
2022 - 03 - 28
4
2022 - 03 - 07
4
2022 - 03 - 01
6
2022 - 02 - 28
6
2022 - 02 - 01
4
2022 - 01 - 24
6
2021 - 12 - 17
4
2021 - 12 - 14
7
2021 - 12 - 09
4
2021 - 12 - 06
8
2021 - 12 - 01
4
2021 - 11 - 18
6
2021 - 11 - 05
5
2021 - 10 - 26
4
2021 - 10 - 25
4
2021 - 10 - 19
4
2021 - 09 - 29
6
2021 - 08 - 16
3
2021 - 08 - 05
4
2021 - 07 - 15
3
2021 - 07 - 06
3
2021 - 06 - 29
4
2021 - 06 - 28
3
2021 - 06 - 17
5
2021 - 06 - 08
4
2021 - 06 - 07
5
2021 - 06 - 03
3
2021 - 05 - 25
3
2021 - 05 - 24
3
2021 - 05 - 06
3
2021 - 05 - 03
5
2021 - 04 - 23
5
2021 - 04 - 13
4
2021 - 03 - 19
3
2021 - 01 - 26
3
2020 - 12 - 29
3
2020 - 12 - 10
3
2020 - 12 - 03
3
Crawled Time
00:00
15
01:00
7
05:00
4
06:00
5
07:00
6
08:00
11
09:00
9
10:00
8
11:00
29
11:20
1
12:00
117
12:15
9
12:20
14
12:30
13
13:00
100
13:15
6
13:20
19
13:30
13
14:00
79
14:15
7
14:20
11
14:30
22
15:00
70
15:15
3
15:20
8
15:30
12
16:00
49
17:00
51
18:00
35
19:00
41
20:00
27
21:00
25
22:00
37
23:00
38
Source
www.biospace.com
901
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
trial
tags :
Clinical-trials-phase-iii
save search
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Published:
2024-04-17
(Crawled : 11:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
-0.09%
|
O:
1.03%
H:
1.66%
C:
-1.11%
obesity
tirzepatide
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea & Vomiting at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Published:
2024-04-15
(Crawled : 13:00)
- biospace.com/
EGRX
|
$4.38
-6.61%
-7.08%
110K
|
Health Technology
|
-2.09%
|
O:
-8.14%
H:
19.55%
C:
18.18%
conference
treatment
pharmaceuticals
for
trial
response
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
Published:
2024-04-15
(Crawled : 13:00)
- biospace.com/
MRNS
|
$1.45
20.83%
17.24%
10M
|
Health Technology
|
-80.85%
|
O:
-75.4%
H:
5.41%
C:
-29.73%
first
update
pharmaceuticals
trial
financial
results
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Published:
2024-04-11
(Crawled : 23:00)
- biospace.com/
TEVA
|
$13.18
0.69%
0.46%
6.6M
|
Health Technology
|
-4.84%
|
O:
-1.01%
H:
2.04%
C:
1.17%
ajovy
for
teva
trial
migraine
china
results
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
Published:
2024-04-03
(Crawled : 22:00)
- biospace.com/
SNGX
|
$0.4963
5.15%
-7.27%
4.2M
|
Health Technology
|
-5.56%
|
O:
-0.33%
H:
3.92%
C:
-9.85%
design
trial
agreement
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published:
2024-03-28
(Crawled : 22:00)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-9.37%
|
O:
0.26%
H:
2.03%
C:
1.57%
first
disease
active
update
trial
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published:
2024-03-26
(Crawled : 12:00)
- biospace.com/
MRNA
|
News
S
|
$103.45
-0.33%
-0.33%
2M
|
Health Technology
|
-6.29%
|
O:
1.29%
H:
0.0%
C:
-3.93%
covid-19
vaccine
positive
trial
results
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
Published:
2024-03-25
(Crawled : 16:00)
- biospace.com/
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-1.09%
|
O:
-100.0%
H:
NaN%
C:
Infinity%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-4.08%
|
O:
0.42%
H:
0.0%
C:
0.0%
fda
cancer
blood
therapy
Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia
Published:
2024-03-22
(Crawled : 08:00)
- biospace.com/
BPTS
|
$0.2905
-17.38%
45K
|
Manufacturing
|
-27.5%
|
O:
-8.72%
H:
13.47%
C:
6.08%
treatment
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published:
2024-03-21
(Crawled : 12:00)
- biospace.com/
MRK
|
$125.37
0.25%
0.1%
6.1M
|
Health Technology
|
1.23%
|
O:
-0.13%
H:
0.4%
C:
-0.06%
ylynk-006
keytruda
lung
merck
update
cancer
cell
trial
plus
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
Published:
2024-03-19
(Crawled : 15:00)
- biospace.com/
SEEL
|
$0.333
-13.53%
-15.65%
720K
|
Health Technology
|
-64.04%
|
O:
-54.24%
H:
71.43%
C:
54.76%
sls-005
update
sclerosis
therapeutics
results
study
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
Published:
2024-03-19
(Crawled : 15:00)
- biospace.com/
CERS
|
$1.63
-2.98%
-3.07%
750K
|
Health Technology
|
-9.68%
|
O:
12.9%
H:
5.71%
C:
-2.86%
corporation
positive
blood
system
topline
trial
cardiovascular
results
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published:
2024-03-12
(Crawled : 12:30)
- biospace.com/
PFE
A
|
$25.42
-1.05%
-0.04%
44M
|
Health Technology
|
-10.4%
|
O:
-0.21%
H:
0.11%
C:
-1.06%
adcetris
positive
trial
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Published:
2024-02-27
(Crawled : 09:00)
- biospace.com/
PTCHF
|
$2.78
19.97%
560
|
n/a
|
4.32%
|
O:
-0.56%
H:
0.0%
C:
-0.38%
AKLI
|
$0.2248
-12.54%
99K
|
|
-50.3%
|
O:
-3.85%
H:
12.67%
C:
6.92%
japan
positive
endeavorrx
adhd
trial
results
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Published:
2024-02-26
(Crawled : 14:30)
- biospace.com/
AKLI
|
$0.2248
-12.54%
99K
|
|
1.44%
|
O:
193.1%
H:
13.69%
C:
-30.36%
endeavorrx
japan
positive
adhd
trial
results
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
Published:
2024-02-23
(Crawled : 21:00)
- biospace.com/
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
6.45%
|
O:
1.29%
H:
1.49%
C:
1.34%
show
We Don’t Know What We Don’t Know: LGBTQIA+ Patient Data and the Struggle for Inclusivity
Published:
2024-02-22
(Crawled : 09:00)
- biospace.com/
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-8.4%
|
O:
0.59%
H:
1.11%
C:
0.92%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
0.65%
|
O:
2.37%
H:
1.51%
C:
0.79%
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Published:
2024-02-20
(Crawled : 14:30)
- biospace.com/
IMNM
|
$17.43
-5.27%
-5.57%
950K
|
Health Technology
|
-32.74%
|
O:
-1.32%
H:
1.76%
C:
-9.8%
al102
tumors
study
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
Published:
2024-02-16
(Crawled : 12:30)
- biospace.com/
KALV
|
$11.67
-1.77%
-1.8%
300K
|
Health Technology
|
-21.07%
|
O:
-0.68%
H:
2.32%
C:
1.36%
sebetralstat
pharmaceuticals
immunology
meeting
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
Published:
2024-02-12
(Crawled : 19:00)
- biospace.com/
ANTX
|
$2.48
0.41%
0.4%
87K
|
|
-87.65%
|
O:
-73.3%
H:
14.23%
C:
-4.49%
lung
disease
trial
← Previous
1
2
3
4
5
6
7
8
9
…
45
46
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.